Ion Beam Applications, SA

Declaration of Voting Results & Voting Rights Announcements • Mar 31, 2017

IBA – TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, March 31, 2017, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notifications received on 25 and 31 March 2017.

Reason for the notification	Upwards crossing followed by a downwards crossing of the 3% threshold further to the acquisition and disposal of shares –and thus voting rights- held as loan collateral
Persons subject to the notification requirement	IBA SA, issuer
Persons that dispose of voting rights	Norges Bank
Transaction date	24/03/2017	29/03/2017
Threshold that is crossed (in %)	3% (statutory	3% (statutory
	threshold)	threshold)
	Upwards crossing	Downwards crossing
	further to the	further to the disposal
	acquisition of voting	of voting rights
	rights
Denominator	29 764 396	29 764 396
Voting rights (number)	897 230	884 930
Voting rights (%)	3.01%	2.97%
Chain of control	N/A

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Caroline Hardy Corporate Legal Counsel +32 10 201 159 caroline.hardy@iba-group.com

Press release | 31/03/2017